Works matching IS 14642662 AND DT 2018 AND VI 19


Results: 138
    1
    2
    3
    4
    5
    6

    Switching to coformulated rilpivirine (RPV), emtricitabine (FTC) and tenofovir alafenamide from either RPV, FTC and tenofovir disoproxil fumarate (TDF) or efavirenz, FTC and TDF: 96‐week results from two randomized clinical trials.

    Published in:
    HIV Medicine, 2018, v. 19, n. 10, p. 724, doi. 10.1111/hiv.12664
    By:
    • Hagins, D;
    • Orkin, C;
    • Daar, ES;
    • Mills, A;
    • Brinson, C;
    • DeJesus, E;
    • Post, FA;
    • Morales‐Ramirez, J;
    • Thompson, M;
    • Osiyemi, O;
    • Rashbaum, B;
    • Stellbrink, H‐J;
    • Martorell, C;
    • Liu, H;
    • Liu, Y‐P;
    • Porter, D;
    • Collins, SE;
    • SenGupta, D;
    • Das, M
    Publication type:
    Article
    7
    8
    9
    10
    11
    12
    13

    Issue Information.

    Published in:
    HIV Medicine, 2018, v. 19, n. 10, p. 1, doi. 10.1111/hiv.12556
    Publication type:
    Article
    14
    15
    16
    17
    18
    19

    Association between exposure to antiretroviral drugs and the incidence of hypertension in HIV‐positive persons: the Data Collection on Adverse Events of Anti‐HIV Drugs (D:A:D) study.

    Published in:
    HIV Medicine, 2018, v. 19, n. 9, p. 605, doi. 10.1111/hiv.12639
    By:
    • Hatleberg, C. I.;
    • Ryom, L.;
    • d'Arminio Monforte, A.;
    • Fontas, E.;
    • Reiss, P.;
    • Kirk, O.;
    • El‐Sadr, W.;
    • Phillips, A.;
    • de Wit, S.;
    • Dabis, F.;
    • Weber, R.;
    • Law, M.;
    • Lundgren, J. D.;
    • Sabin, C.;
    • the Data Collection on Adverse Events of Anti‐HIV Drugs (D:A:D) Study Group
    Publication type:
    Article
    20
    21
    22
    23
    24
    25
    26

    Issue Information.

    Published in:
    HIV Medicine, 2018, v. 19, n. 9, p. 1, doi. 10.1111/hiv.12555
    Publication type:
    Article
    27
    28
    29
    30
    31
    32
    33
    34
    35
    36

    Scale‐up of HIV self‐testing.

    Published in:
    HIV Medicine, 2018, v. 19, n. 8, p. e72, doi. 10.1111/hiv.12618
    By:
    • Jakobsen, S. F.;
    • Raben, D.;
    • Sperle, I.;
    • Lazarus, J. V.;
    • James, C.;
    • Mendão, L.;
    • De Wit, J.;
    • Platteau, T.;
    • Von Lingen, A‐i;
    • Corbelli, G. M.;
    • Antoniadi, C.;
    • Casabona, J.;
    • West, B.;
    • Rockstroh, J.;
    • Delpech, V.;
    • The Hiv In Europe Steering Committee
    Publication type:
    Article
    37
    38
    39

    Issue Information.

    Published in:
    HIV Medicine, 2018, v. 19, p. 1, doi. 10.1111/hiv.12608
    Publication type:
    Article
    40
    41

    Welcome Letter.

    Published in:
    HIV Medicine, 2018, v. 19, p. 3, doi. 10.1111/hiv.12648
    Publication type:
    Article
    42
    43

    First‐line antiretroviral therapy with efavirenz plus tenofovir disiproxil fumarate/emtricitabine or rilpivirine plus tenofovir disiproxil fumarate/emtricitabine: a durability comparison.

    Published in:
    HIV Medicine, 2018, v. 19, n. 7, p. 475, doi. 10.1111/hiv.12628
    By:
    • Taramasso, L.;
    • Di Biagio, A.;
    • Maggiolo, F.;
    • Tavelli, A.;
    • Lo Caputo, S.;
    • Bonora, S.;
    • Zaccarelli, M.;
    • Caramello, P.;
    • Costantini, A.;
    • Viscoli, C.;
    • d'Arminio Monforte, A.;
    • Cozzi‐Lepri, A.;
    • the Italian Cohort Naive Antiretrovirals (ICONA) Foundation Study Group
    Publication type:
    Article
    44
    45
    46
    47
    48
    49
    50